Presentation

Company Profile
Corline develops, manufactures and markets heparin-based solutions to improve kidney transplantation, cell therapies and applications in the evolving field of regenerative medicine. Its main project is Renaparin to improve the outcome of kidney transplantations by reducing the ischemia/reperfusion injury, which often occurs when a kidney is connected to the recipient. The company also partner with medical device companies to improve blood and biocompatibility of medical device implants. The company is based in Uppsala, Sweden and listed on Nasdaq First North in Stockholm.

Recent highlights
On 2 August, the company announced that it had signed a term sheet with a US company for the use ot its CHS coating technology. If the term sheet is executed, Corline expect it to eventually generate revenues to Corline exceeding SEK 50m annually.

Outlook
The company aims to start the phase ll study with Renaparin in 2021. Both the FDA and EMA have provided Corline with similarly positive feedback regarding the planned Ph2 study with Renaparin, which means a joint clinical trial can be performed.